PARP1-IN-40 is a highly selective and orally active PARP1 inhibitor with an IC50 of 0.19 nM for PARP1 and 26 nM for PARP2. By inhibiting PARP1, it induces DNA damage accumulation, effectively killing tumor cells. It demonstrates significant antitumor activity against BRCA-mutated MDA-MB-436 cells. Additionally, PARP1-IN-40 can be used in combination with chemotherapy for related cancer research.
Target:
PARP
* VAT and and shipping costs not included. Errors and price changes excepted
